Who owns LENZ Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of LENZ from SEC Form 13F filings across 145 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 145 institutions disclosed 34.7M shares of LENZ Therapeutics, Inc. worth $197.3M — about 110.6% of shares outstanding; the largest disclosed holder is RA CAPITAL MANAGEMENT, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
145
13F holders
$197.3M
value, 2026 filers
110.6%
of shares outstanding (34.7M sh)
29
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of LENZ's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 4.2M | $23.7M | 0.2% | 13.3% | 0.0% |
| 2 | Alpha Wave Global, LP | 3.6M | $20.5M | 0.3% | 11.5% | 0.0% |
| 3 | FMR LLC | 3.6M | $20.2M | 0.0% | 11.3% | -1.1% |
| 4 | Versant Venture Management, LLC | 2.7M | $15.1M | 9.3% | 8.5% | 0.0% |
| 5 | BlackRock, Inc. | 2.3M | $13.0M | 0.0% | 7.3% | +15.9% |
| 6 | Squarepoint Ops LLC | 1.7M | $9.9M | 0.0% | 5.6% | +16.0% |
| 7 | Aberdeen Group plc | 1.5M | $8.8M | 0.0% | 4.9% | +33.9% |
| 8 | MILLENNIUM MANAGEMENT LLC | 1.5M | $8.6M | 0.0% | 4.8% | +73.5% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 1.1M | $6.2M | 0.0% | 3.5% | +5.4% |
| 10 | 72 Investment Holdings, LLC | 1.0M | $5.8M | 11.6% | 3.2% | 0.0% |
| 11 | Blue Owl Capital Holdings LP | 756,722 | $4.3M | 0.6% | 2.4% | +49.3% |
| 12 | C WorldWide Group Holding A/S | 700,000 | $4.0M | 0.1% | 2.2% | 0.0% |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 564,662 | $3.2M | 0.0% | 1.8% | +7.6% |
| 14 | Trexquant Investment LP | 497,526 | $2.8M | 0.0% | 1.6% | +132.0% |
| 15 | MARSHALL WACE, LLP | 493,099 | $2.8M | 0.0% | 1.6% | +207.7% |
| 16 | Qube Research & Technologies LtdNEW | 482,195 | $2.7M | 0.0% | 1.5% | new |
| 17 | MORGAN STANLEY | 472,995 | $2.7M | 0.0% | 1.5% | -27.1% |
| 18 | PRIMECAP MANAGEMENT CO/CA/ | 472,200 | $2.7M | 0.0% | 1.5% | 0.0% |
| 19 | TANG CAPITAL MANAGEMENT LLC | 451,114 | $2.6M | 0.1% | 1.4% | 0.0% |
| 20 | Alyeska Investment Group, L.P. | 438,882 | $2.5M | 0.0% | 1.4% | -5.3% |
| 21 | STATE STREET CORP | 406,674 | $2.3M | 0.0% | 1.3% | +1.1% |
| 22 | CITADEL ADVISORS LLCNEW | 363,229 | $2.1M | 0.0% | 1.2% | new |
| 23 | TWO SIGMA INVESTMENTS, LP | 285,584 | $1.6M | 0.0% | 0.9% | -43.0% |
| 24 | Rock Springs Capital Management LP | 257,460 | $1.5M | 0.1% | 0.8% | 0.0% |
| 25 | BANK OF AMERICA CORP /DE/ | 255,410 | $1.5M | 0.0% | 0.8% | -53.4% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.